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ABSTRACT 
The Role of p53 and Estradiol on the Suppression of Sporadic Tumor Formation in the Colon 
  
Jenna Jeffrey 
Department of Nutrition and Food Science 
Texas A&M University 
 
Research Advisor: Dr. Clinton Allred 
Department of Nutrition and Food Science 
Texas A&M University 
 
 
 Previous studies have shown a correlation between estradiol (E2) levels in women and the 
decreased risk of colon cancer. E2 serves a protective role in the colon by increasing apoptosis in 
non-malignant colonocytes that have become damaged due to different stressors within the body 
[1]. The p53 protein plays an important role at the cellular level by detecting DNA damage and 
regulating cell cycle progression. A proposed mechanism suggested by in vitro studies, indicates 
that the protective effects of E2 on tumor formation within the colon is mediated by p53 [2]. The 
roles of E2 and p53 on tumor development in the colon were analyzed through the identification 
of visible tumors and proliferation in the distal colons of C57/BL-6J female mice. E2 suppressed 
tumor development in the presence of a functional p53 protein. Proliferation was enhanced in 
colonic tissue lacking a functional p53, thus suggesting the importance of p53 in suppressing 
tumor development. Collectively, our findings illustrate the importance of a functional p53 
protein in tumor development and its role in mediating E2 protective effects within the colon.  
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CHAPTER I 
INTRODUCTION 
 
Colon Cancer and p53 
Research focused on the study of colorectal cancer (CRC) represents an important topic 
worldwide. It has been reported that CRC is the second leading cause of cancer-related death 
behind lung cancer [3]. Many avenues of research are being conducted in order to better 
understand the physiological mechanism behind causation and potentially prevention of CRC. 
Development past the fifth decade of life, Inflammatory Bowel Diseases (IBD), smoking, 
alcohol consumption, diet, and a sedentary lifestyle are only a few of the many risk factors in the 
development of CRC [4]. Improvements made in health care are reducing death from CRC and 
decreasing incidence of the disease, through improved screening methods and removal of 
adenomatous polyps [5].   
One of the most important defenses that the body has in fighting the development of 
cancer is through the tumor suppressor gene p53. A variety of cancers arise from a mutation in 
the p53 gene [6]. The high incidence of mutations in p53 qualifies it as an important target for 
cancer research. Mutation in p53 results from the inactivation of alleles apart of chromosome 
17p (Ch17p) [7]. In cases of most colorectal tumors the p53 gene has been altered, attributing the 
loss of p53 function to the transition from an adenoma to a malignant carcinoma [4]. Lack of a 
functioning p53 gene prevents normal activity of apoptosis to rid the tissue of damaged cells and 
loses the ability to suppress cell cycle when cells become to plentiful.  
Tumorigenesis arises from dysregulation of cell growth and proliferation [8]. In response 
to an oncogenic stress, p53 induces transcriptional and translational responses in order to prevent 
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abnormal cell growth by inducing cell-cycle arrest through down-regulation of cell-cycle genes 
[8]. The mechanism by which p53 contributes to regulating cell growth is through translational 
repression of key translational factors and ribosomal proteins [8]. The colon is a rapidly 
proliferating organ, where damages or mutations within DNA can quickly arise, thus stimulating 
the activation of the p53 protein [9]. A delay is made between the G1 and S phase, where DNA 
repair can be carried out to fix the point mutation made [9]. These alterations initiated by p53, 
suppress tumor formation by not allowing the damaged cell to proceed into the next phase of the 
cell cycle. 
There are two pathways in which CRC can develop; a prolonged duration of chronic 
inflammation of the gut or spontaneously [10]. A model to better illustrate the onset of 
inflammation-associated CRC can best be seen through those suffering from IBD. Those 
suffering from IBD have an increased risk of CRC due to the prolonged existence of mucosal 
inflammation [11]. Environmental and internal agents elicit an immune response from the 
damaged colonic tissue, resulting in the need for regeneration and proliferation [12]. In the event 
that the tissue is not repaired, the surrounding microenvironment continues efforts made in 
restoration and repair, leading to the continuation of unregulated proliferation and accumulation 
of genetic errors [12].  
Sporadic CRC accounts for 70% of all detected colorectal cancers [4].  The mechanism 
behind the initiation of sporadic CRC is derived from point mutations in oncogenes, tumor 
suppressor genes, and genes responsible for DNA repair [4]. Point mutations may arise during 
life through exposure to mechanical and chemical agents. The progression of tumor formation 
begins with an adenoma and concludes in the transitional formation of a carcinoma. Most, but 
not all, non-malignant adenomas arise from a mutation first transcribed in the adenomatous 
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polyposis coli (APC), a tumor suppressor gene [4]. An APC mutation results in abnormal 
function of the cell due to a truncated protein product, effecting the region of protein essential for 
either tumor progression or suppression [13]. Mutations in KRAS and TP53 progress after a 
mutation in APC [4]. A mutation in KRAS increases cell proliferation as a result of constant 
activation of mitogen-activated protein (MAP) kinase. TP53 encodes for the tumor suppresser 
gene p53. A mutation in TP53 would result in unregulated entry into the cell cycle [4].  
While both types of cancers occur through a multistep development with accumulations 
of numerous mutations, one key difference between the two cancers can best be seen in the 
timing of a genetic mutation in p53 [11]. A mutation in p53 arises earlier in inflammation-
associated CRC when compared to the sequence of events leading to the mutation in sporadic 
CRC [11]. Studies have shown that in the event of mutation in the tumor suppressor gene p53, 
the mechanism for cell regulation becomes compromised, allowing for a tumor to progress. Not 
only is a functional p53 protein critical in the suppression of tumor development in the colon but 
recent studies and census data have suggested that E2 also protects against CRC [14].   
  
Colon Cancer and Estradiol 
The protective role of E2 in the suppression of CRC can best be supported by the findings 
from the Women’s Health Initiative. A lower incidence of CRC was found among 
postmenopausal women receiving hormone replacement therapy (HRT), when compared to those 
receiving the placebo not made of estrogen and progesterone [14]. Literature also suggests the 
protective roles of E2 through the decreased risk in the development of CRC seen in females with 
IBD compared to males with IBD [15]. In vivo studies have also illustrated the protective role 
that E2 plays against preneoplastic lesions [1]. E2 serves protective effects in the premalignant 
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carcinogenesis stage through a reduction in aberrant crypt foci (ACF), which are lesions that 
serve as a good indication for tumor development [1]. Collectively, these data suggest that E2 has 
protective effects within the colon by suppressing the development of tumors.   
Our laboratory is investigating the role that both p53 and E2 play in congruence with one 
another. Through in vitro and in vivo studies, the presence of E2 significantly increased apoptosis 
in young adult mouse colonocytes and colonic epithelium [1]. The induction of apoptosis 
indicates that E2 triggers p53 activity. Further investigation showed that E2 provides protective 
effects within the colon when p53 is expressed, and suppressed or completely lost in the absence 
of p53 [2]. In vitro studies suggest that the physiological actions of E2 in colonocytes is, in part, 
mediated through p53[2].  
Related to the data presented here, an in vivo study conducted by Yoo (2015) [16], 
investigated the targeted deletion of p53 in the gastrointestinal tract. Azoxymethane (AOM), a 
colon specific carcinogen, was used to induce sporadic tumors. Colon carcinogenesis occurs 
frequently in the distal part of the colon with the administration of AOM, analogous to the 
localization seen in sporadic CRC in humans [10]. AOM initiates tumor formation by alkylation 
of DNA, creating base mispairings [10]. Yoo investigated ACFs, high multiplicity ACFs, and 
visible tumor formation. With theses findings, our main focus for this study was the examination 
of proliferation with a varying presence of p53 and exposure to E2, providing insight into the role 
of estrogen signaling on sporadic tumor development.  
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CHAPTER II 
METHODS 
 
Mouse Model 
Sexually mature C57BL/6 female Tp53Flox/Flox mice were bred with Villin-CRE mice 
through multiple generations in order to produce an offspring containing Tp53Flox/Flox/CRE and 
Tp53Flox/Flox that were utilized in the study. These particular mice were genetically altered to 
loose function of p53 in the gastrointestinal tract. At time of initiation, mice were ovariectomized 
(OVX) for regulation of E2, treated with an implanted pellet, and placed on a phytoestrogen-free 
diet ad libitum. The control implant administered was a 20mg cholesterol pellet, while the 
treatment group was exposed to a 19 mg cholesterol and 1 mg E2 pellet. For the induction of 
sporadic tumors, six weekly injections of AOM at 10mg/kg body weight were administered two 
weeks after ovariectomy. Replacement of cholesterol or cholesterol and E2 pellet occurred at 56 
days. Sacrifice was carried out on day 98. Two hours prior to termination, mice were injected 
with 5-bromo-2’ –deoxyuridine (BrdU) in order to perform the proliferation assay. Tissues were 
excised and fixed with the use of 4% paraformaldehyde (PFA), for further analysis of 
proliferative cells within the colonic crypts.   
 
Immunohistochemistry 
Colonic tissue collected was stained for proliferation using the protocol set out by the 
laboratory. The protocol began with deparaffinizing and rehydrating the tissues. Endogenous 
peroxidase activity was quenched. Antigen retrieval followed after. The primary antibody was 
than administered through a preparation of a 1:20 dilution of AnitBrdU in PBS w/ 1% BSA. The 
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tissues were than placed in a humidified chamber at 4oC overnight. The following day, the 
secondary antibody was than applied through a prepared dilution of 1:200 of HRP Conjugated 
Goat-anti-Mouse Antibody in PBS with 1%BSA. The tissues were placed in a humidified 
chamber for one hour. 1% Diaminobenzidine solution was placed on the tissues for ten minutes. 
Hematoxylin was than used to counterstain the tissues. The final preparations were dehydrating 
the tissues and mounting with permount.  
 
Determination of Proliferation 
 Slides were viewed using bright-field microscopy. 20 crypts from each animal were 
analyzed. Each crypt was split sagittally down the center of the crypt. The right side of the crypt 
was used consistently throughout all animals, as to keep from any bias in occurring. The crypt 
was further divided into three transverse sections; the bottom, middle, and top portion of the 
crypt. Proliferative cells were counted within each region, and recorded as a percentage. The 
percentage of all proliferative cells to number of cells within the crypt was also recorded.  
 
Statistical Analysis 
 All data are presented as mean ± SEM. Data from proliferation stains were transformed 
to percentage of cells within the crypt. Analysis for all data was determined using one-way 
ANOVA with Student’s t post hoc test. Differences were considered significant if P<0.05. All 
statistical analyses were performed using Graphpad Prism version 6.0 for Mac OS X, Graphpad 
Software, La Jolia California USA, www.graphpad.com.   
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CHAPTER III 
RESULTS 
 
p53 and E2 on visible tumor formation  
In order to investigate the effect of E2 and p53 on sporadic tumor formation within the 
colon, we first analyzed quantitative results made by p53 and E2 in the development of visible 
tumor formation. Tumor number was counted using microscopic analysis. In mice with WT p53, 
treatment with E2 resulted in a significantly lower number of visible tumors when compared to 
the respective control (Fig 1). In the absence of p53, mice treated with E2 also had a significantly 
lower number in tumor formation when compared to the respective control (Fig. 1). There was 
no significant difference between the two genotypes when treated with the control, as well as 
with treatment with E2 (Fig 1).  
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p53 and E2 on proliferation in the colonic crypt 
In order to better understand the mechanism behind E2 providing protective effects 
against the production of tumors and the role that p53 plays, amount of proliferation within the 
colonic crypt within each group was investigated. Loss of p53 resulted in a significant increase in 
proliferation in both control and E2 treated groups (Fig. 2). A significant increase in proliferation 
was also found in mice with the presence of p53 and treatment of E2 (Fig 2).  
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Fig. 1 In vivo effect of p53 and E2 on visible tumor development during induced tumor formation with 
the colon. Mean (n≥12) ± SEM. Bars without a common letter differ; p<0.05.  
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Fig. 2 In vivo effect of p53 and E2 on percent proliferation in the colonic crypt during induced 
sporadic tumor formation. Mean (n≥12) ± SEM. Bars without a common letter differ; p<0.05.  
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CHAPTER IV 
DISCUSSION 
 
Studies have shown that E2 provides protective effects within the colon. The Women’s 
Health Initiative study reported a statistically significant decrease in CRC in postmenopausal 
women receiving HRT in the form of supplemented E2 and progesterone [14]. The protective 
effects of E2 can best be seen through the mechanism of ERβ serving as a mediator. There are 
two types of estrogen receptors found throughout the body: estrogen receptor α (ERα) and 
estrogen receptor β (ERβ). Cells of the kidney, intestinal mucosa, prostate gland, and endothelial 
contain ERβ, whereas the endometrium, ovarian stroma, and breast cancer cells contain ERα 
[17]. ERβ protein is the predominant form in colonic epithelium with no detection of ERα [18]. 
Although ERα and ERβ share structural similarities they differ in that they possess opposing 
roles. ERα is instrumental in the breast and uterine tissue by inducing proliferation for growth 
and development of the tissue, ERβ serves as an antagonist to ERα by counteracting the 
stimulation of proliferation [19].   
Previous experimentation in our laboratory investigated the mediation of E2, by ERβ, as it 
relates to suppression in tumor formation. A comparison of WT to ERβ knockout mice resulted 
in significantly fewer ACFs and increased apoptosis in WT mice treated with E2, compared to 
those not treated with the control [1]. Protection of E2 was lost entirely in ERβ knockout where 
significance was not detected in the presence or absence of E2 [1]. For E2 to impart protective 
effects within the colon, ERβ must be expressed.  
Our laboratory further investigated this mechanism and found p53 to play a major role in 
E2 protective effects within the colon, through the observation of induced apoptosis in non-
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malignant colonocytes [2]. Their results were indicative of E2 being mediated through p53. p53 
is a transcription factor that is essential in the developmental process of a cell. Through 
regulation of gene expression in response to being exposed to different stress signals, p53 
induces apoptosis, DNA repair, and/or initiation of cell cycle arrest. The tumor suppressor gene 
p53 is the most commonly mutated gene found in cancer [20]. A functional p53 protein is crucial 
in regulating tumorigenesis and stopping the development of tumors.  
The reciprocal action of ERα and ERβ, and the ratio found amongst the organs, is key in 
understanding the susceptibility of estrogen- induced carcinogenesis [21]. Binding of estrogens 
to ERα induces a cancer promoting response, whereas binding to ERβ provides protective effects 
[21]. In the presence of E2, colonic expression of ERα is suppressed while ERβ expression 
increases [21]. Previous data from our laboratory has shown in young adult mouse colonocyte 
(YAMC) cells, a 200-fold increase in ERβ to ERα expression [2]. With high abundance of ERβ 
expression found in colonic tissue, it is believed that E2 possesses protective effects in the 
presence of p53, through ERβ. Findings from our study showed evidence of this concept through 
a significant reduction in the number of visible tumors found in the presence of p53 and 
treatment of E2.   
Not only did E2 reduce the number of visible tumors in mice expressing p53, tumor 
formation was also significantly reduced in mice not expressing a functional p53 protein. This 
finding illustrates that whether p53 is expressed or not, E2 provides protective effects within the 
colon. With literature providing evidence of the mediation of E2 through p53, our data also 
suggests that there is another mediator channeling the protective effect of E2. Further 
investigation should be conducted to explain the mechanism behind E2 protective effects in the 
absence of p53.  
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Experimentation outside of our laboratory illustrated the role p53 plays in blocking cell 
proliferation and arresting cell growth through the induction of transcriptional repression and 
translational inhibition [8]. Due to this instrumental process, the loss of expression in p53 
exposes the colon to potential tumor development. Our study has shown that in the absence of 
p53, a statistically significant increase in proliferation was observed in the absence and presence 
of E2. p53 is instrumental in reducing tumor formation, through regulation of proliferation. In the 
absence of p53, the cell looses its ability to regulate growth, and uncontrolled proliferation may 
result.  
Further investigation in this model, including analyzing apoptosis, should be carried out 
to further explain the mechanism by which p53 contributes to a reduction in sporadic tumor 
formation when in the presence of E2. Our results in the p53 WT group treated with E2 were not 
consistent with our original hypothesis. The increase in proliferation seen within this group was 
not consistent with our proposed mechanism. An increase in proliferation is indicative of 
potential tumor development. We believe that there is a timing aspect as to when E2 provides 
protective or harmful effects within the colon, thus providing reasoning behind our results.  
The Women’s Health Initiative study, as previously stated, found that HRT resulted in a 
decreased risk in CRC [14]. However, when taking E2 and progesterone at time of diagnosis, 
those suffering from CRC had a more advanced progression of the cancer when compared to 
those treated with the placebo [14]. A mechanism to better explain this effect is through the 
expression of ERβ. In normal colonic epithelial cells, ERβ expression is at its greatest [22]. As 
the tumor begins to form, expression of ERβ has been seen to decrease in expression in 
adenomatous tissue, and further decreases in expression as it than transitions into the formation 
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of a carcinoma [22]. It is plausible that the increased proliferation seen in this subgroup was due 
to a transition to a less expressed ERβ colonic tissue.  
Overexpression in ERβ has been shown to increase p53 signaling, thus inducing 
apoptosis and anti-proliferation [23]. With this is mind, as an adenoma progresses into a 
malignant carcinoma, ERβ expression decreases through the tumor development [22]. This 
action inhibits stimulatory effects on p53, allowing the cell to become unregulated and grow 
uncontrollably. We believe that the colonic tissue had transitioned, where ERβ expression had 
been suppressed. The stimulatory effect that ERβ has on p53 would be inhibited, thus resulting in 
an increase in proliferation.  
In conclusion, the loss of p53 significantly increased proliferation. E2 has protective 
affects within the colon by suppressing tumor formation in the presence or absence of p53. The 
data suggests that there is an alternate pathway by which E2 can protect against sporadic tumor 
formation in the colon. Further investigation should be carried out to provide more insight into 
the mechanism of E2 signaling.      
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